

LA JOLLA PHARMACEUTICAL CO
Form 4
June 19, 2009

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
BIOMARIN PHARMACEUTICAL
INC

2. Issuer Name and Ticker or Trading Symbol
LA JOLLA PHARMACEUTICAL
CO [LJPC]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
105 DIGITAL DRIVE
(Street)

3. Date of Earliest Transaction
(Month/Day/Year)
06/17/2009

____ Director
____ Officer (give title below)
__X__ 10% Owner
____ Other (specify below)

NOVATO, CA 94949

(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
__X__ Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
				Code V	Amount	(A) or (D)	Price
Common Stock	06/17/2009		S	960,950	D	0.2248	9,212,170
						<u>(1)</u>	
Common Stock	06/18/2009		S	2,198,825	D	0.2096	7,013,345
						<u>(2)</u>	
Common Stock	06/19/2009		S	2,546,958	D	0.2059	4,466,387
						<u>(3)</u>	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 3)
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	---

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BIOMARIN PHARMACEUTICAL INC 105 DIGITAL DRIVE NOVATO, CA 94949		X		

Signatures

/s/ G. Eric Davis, Vice President, General Counsel
Date: 06/19/2009

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - (1) This transaction was executed in multiple trades at prices ranging from \$0.22 to \$0.2403. The reported price reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission ("SEC") staff, the Issuer or a shareholder of the Issuer full information regarding the number of shares purchased at each separate price.
 - (2) This transaction was executed in multiple trades at prices ranging from \$0.20 to \$0.2248. The reported price reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request by the SEC staff, the Issuer or a shareholder of the Issuer full information regarding the number of shares purchased at each separate price.
 - (3) This transaction was executed in multiple trades at prices ranging from \$0.20 to \$0.2201. The reported price reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request by the SEC staff, the Issuer or a shareholder of the Issuer full information regarding the number of shares purchased at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.